Jupiter Endovascular develops endovascular devices utilizing Transforming Fixation (TFX) technology, which allows catheters to transition between flexible and firm states during procedures. This innovation aims to simplify complex interventions in soft vascular structures, initially targeting pulmonary embolism treatment. The technology seeks to expand therapeutic options for cardiovascular conditions currently underserved by existing catheter systems.
Funding
$21M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for removing thrombi in patients with pulmonary embolism (PE) have limitations in safety and control, potentially leading to incomplete removal and adverse outcomes. Existing catheter-based interventions may lack the precision of surgical techniques, while traditional surgery carries significant risks.
Solution
Jupiter Endovascular is developing the Vertex Pulmonary Embolectomy System, which combines the precision of surgical techniques with the safety and simplicity of catheter-based interventions using their proprietary Endoportal Control™ technology. This system aims to improve the treatment of pulmonary embolism by enabling safer, more controlled procedures for thrombus removal. The Vertex system is designed to navigate the pulmonary vasculature, precisely target and remove clots, and minimize the risk of complications associated with traditional methods. By integrating surgical precision with endovascular access, the system offers a novel approach to PE treatment, potentially leading to improved patient outcomes and reduced recovery times. The company's focus is on reimagining therapies for cardiovascular diseases, with pulmonary embolism as its initial target.
Target Audience
The primary target audience includes interventional cardiologists, vascular surgeons, and other medical professionals specializing in the treatment of pulmonary embolism and cardiovascular diseases.
Features
- Endoportal Control™ technology for enhanced surgical precision during catheter-based interventions.
- Minimally invasive approach to reduce patient trauma and recovery time.
- Precise targeting and controlled removal of thrombi within the pulmonary vasculature.
- Designed to address the limitations of existing thrombus removal methods.